Neurocrine Biosciences | NBIX - Pre Tax Profit


Neurocrine Biosciences reported $246.8M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
AbbVie USD 5.57B 2.9B Mar/2026
Acadia Pharmaceuticals USD 3.98M 22.34M Mar/2026
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
ALKERMES USD -61.93M 122.3M Mar/2026
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
Amgen USD 1.51B 2.41B Dec/2025
Biogen USD 377.7M 433.7M Mar/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Cytokinetics USD -206.03M 23M Mar/2026
Enanta Pharmaceuticals USD -22.71M 95.08M Dec/2024
Exelixis USD 267.69M 15M Mar/2026
Gilead Sciences USD 2.08B 1.56B Dec/2025
Halozyme Therapeutics USD 180.33M 281.18M Mar/2026
Incyte USD 343.6M 46.34M Mar/2026
Ionis Pharmaceuticals USD -93M 135M Mar/2026
Nektar Therapeutics USD -34.7M 2.35M Dec/2025
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Pfizer USD 5.18B 6.82B Mar/2026
Prothena USD -21.58M 15.33M Dec/2025
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Repligen USD 19.11M 2M Dec/2025
Rigel Pharmaceuticals USD -1.03M 7.22M Jun/2024
Sarepta Therapeutics USD 343.17M 750.85M Mar/2026
Teva Pharmaceutical Industries USD 753M 662M Mar/2026
Ultragenyx Pharmaceutical USD -184M 56M Mar/2026
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026
Xoma USD 15.98M 24.58M Jun/2024